Benefits of Novartis psoriasis drug outweighs risk: FDA staff
October 16, 2014 at 08:34 AM EDT
Oct 16 (Reuters) - The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said.
